<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26596952</PMID><DateCompleted><Year>2016</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1098-6596</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>2</Issue><PubDate><Year>2016</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Antimicrobial agents and chemotherapy</Title><ISOAbbreviation>Antimicrob Agents Chemother</ISOAbbreviation></Journal><ArticleTitle>A Conserved Inhibitory Mechanism of a Lycorine Derivative against Enterovirus and Hepatitis C Virus.</ArticleTitle><Pagination><StartPage>913</StartPage><EndPage>924</EndPage><MedlinePgn>913-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.02274-15</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) (Picornaviridae family) and hepatitis C virus (HCV) (Flaviviridae family) are the causative agents of human hand, foot, and mouth disease (HFMD) and hepatitis C, resulting in a severe pandemic involving millions of infections in the Asia-Pacific region and worldwide. The great impact of EV71 and HCV on public health highlights the need to further our understanding of the biology of these two viruses and develop effective therapeutic antivirals. Here, we evaluated a total of 32 lycorine derivatives and demonstrated that 1-acetyllycorine suppressed the proliferation of multiple strains of EV71 in various cells. The results of the drug resistance analysis revealed that 1-acetyllycorine targeted a phenylalanine (F76) in EV71 2A protease (2A(pro)) to stabilize the conformation of a unique zinc finger. Most interestingly, the zinc binding site in EV71 2A(pro) is the exclusive homolog of HCV NS3 among all viruses. Further analysis revealed that 1-acetyllycorine also inhibits HCV with high efficacy, and the mutation on R118 in HCV NS3, which corresponds to F76 in EV71 2A(pro), confers the resistance of HCV to 1-acetyllycorine. These results revealed a conserved mechanism of 1-acetyllycorine against EV71 and HCV through targeting viral proteases. We also documented the significant synergistic anti-EV71 and anti-HCV effects of 1-acetyllycorine with reported inhibitors, supporting potential combination therapy for the treatment of EV71 and HCV infections.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016, American Society for Microbiology. All Rights Reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>College of Pharmacy and State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yaxin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>College of Pharmacy and State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China Collaborative Innovation Center for Biotherapy, Tsinghua University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>College of Pharmacy and State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China Collaborative Innovation Center for Biotherapy, Tsinghua University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>College of Pharmacy and State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qing</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Tsinghua-Peking Center for Life Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, China School of Medicine, Tsinghua University, Beijing, China Collaborative Innovation Center for Biotherapy, Tsinghua University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Qizhen</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Tsinghua University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shang</LastName><ForeName>Luqing</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>College of Pharmacy and State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Zheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>College of Pharmacy and State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China zheng_yin@nankai.edu.cn sunyn@moon.ibp.ac.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yuna</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Science, Beijing, China zheng_yin@nankai.edu.cn sunyn@moon.ibp.ac.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>11</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Antimicrob Agents Chemother</MedlineTA><NlmUniqueID>0315061</NlmUniqueID><ISSNLinking>0066-4804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000611892">1-acetyllycorine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047151">Amaryllidaceae Alkaloids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C084422">NS3 protein, hepatitis C virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010617">Phenanthridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>I9Q105R5BU</RegistryNumber><NameOfSubstance UI="C015330">lycorine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D047151" MajorTopicYN="N">Amaryllidaceae Alkaloids</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010617" MajorTopicYN="N">Phenanthridines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040681" MajorTopicYN="N">Structural Homology, Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26596952</ArticleId><ArticleId IdType="pmc">PMC4750679</ArticleId><ArticleId IdType="doi">10.1128/AAC.02274-15</ArticleId><ArticleId IdType="pii">AAC.02274-15</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yang Y, Wang H, Gong E, Du J, Zhao X, McNutt MA, Wang S, Zhong Y, Gao Z, Zheng J. 2009. Neuropathology in 2 cases of fatal enterovirus type 71 infection from a recent epidemic in the People's Republic of China: a histopathologic, immunohistochemical, and reverse transcription polymerase chain reaction study. Hum Pathol 40:1288&#x2013;1295. doi:10.1016/j.humpath.2009.01.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humpath.2009.01.015</ArticleId><ArticleId IdType="pubmed">19386354</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, Mao N, Xu S, Zhu S, Cui A, Zhang Y, Yan D, Li Q, Dong X, Zhang J, Zhao Y, Wan J, Feng Z, Sun J, Wang S, Li D, Xu W. 2010. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J 7:94. doi:10.1186/1743-422X-7-94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-94</ArticleId><ArticleId IdType="pmc">PMC2885340</ArticleId><ArticleId IdType="pubmed">20459851</ArticleId></ArticleIdList></Reference><Reference><Citation>Pol S, Vallet-Pichard A, Corouge M, Mallet VO. 2012. Hepatitis C: epidemiology, diagnosis, natural history and therapy. Contrib Nephrol 176:1&#x2013;9. doi:10.1159/000332374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000332374</ArticleId><ArticleId IdType="pubmed">22310776</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavanchy D. 2009. The global burden of hepatitis C. Liver Int 29(Suppl 1):74&#x2013;81. doi:10.1111/j.1478-3231.2008.01934.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1478-3231.2008.01934.x</ArticleId><ArticleId IdType="pubmed">19207969</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Wang Y, Shan C, Sun Y, Xu P, Zhou H, Yang C, Shi PY, Rao Z, Zhang B, Lou Z. 2013. Crystal structure of enterovirus 71 RNA-dependent RNA polymerase complexed with its protein primer VPg: implication for a trans mechanism of VPg uridylylation. J Virol 87:5755&#x2013;5768. doi:10.1128/JVI.02733-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02733-12</ArticleId><ArticleId IdType="pmc">PMC3648134</ArticleId><ArticleId IdType="pubmed">23487447</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Wang Y, Shan C, Chen C, Xu P, Song M, Zhou H, Yang C, Xu W, Shi PY, Zhang B, Lou Z. 2012. Enterovirus 71 VPg uridylation uses a two-molecular mechanism of 3D polymerase. J Virol 86:13662&#x2013;13671. doi:10.1128/JVI.01712-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01712-12</ArticleId><ArticleId IdType="pmc">PMC3503026</ArticleId><ArticleId IdType="pubmed">23055549</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H, Sun Y, Guo Y, Lou Z. 2013. Structural perspective on the formation of ribonucleoprotein complex in negative-sense single-stranded RNA viruses. Trends Microbiol 21:475&#x2013;484. doi:10.1016/j.tim.2013.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2013.07.006</ArticleId><ArticleId IdType="pubmed">23953596</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC. 2002. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26:91&#x2013;107. doi:10.1111/j.1574-6976.2002.tb00601.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6976.2002.tb00601.x</ArticleId><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Racaniello VR. 2001. Picornaviridae: the viruses and their replication, p 685&#x2013;722. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 4th ed Lippincott Williams &amp; Wilkins, Philadelphia, PA.</Citation></Reference><Reference><Citation>Wu Y, Lou Z, Miao Y, Yu Y, Dong H, Peng W, Bartlam M, Li X, Rao Z. 2010. Structures of EV71 RNA-dependent RNA polymerase in complex with substrate and analogue provide a drug target against the hand-foot-and-mouth disease pandemic in China. Protein Cell 1:491&#x2013;500. doi:10.1007/s13238-010-0061-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-010-0061-7</ArticleId><ArticleId IdType="pmc">PMC4875138</ArticleId><ArticleId IdType="pubmed">21203964</ArticleId></ArticleIdList></Reference><Reference><Citation>Moradpour D, Brass V, Gosert R, Wolk B, Blum HE. 2002. Hepatitis C: molecular virology and antiviral targets. Trends Mol Med 8:476&#x2013;482. doi:10.1016/S1471-4914(02)02395-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1471-4914(02)02395-X</ArticleId><ArticleId IdType="pubmed">12383770</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyoda H, Nicklin MJ, Murray MG, Anderson CW, Dunn JJ, Studier FW, Wimmer E. 1986. A second virus-encoded proteinase involved in proteolytic processing of poliovirus polyprotein. Cell 45:761&#x2013;770. doi:10.1016/0092-8674(86)90790-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(86)90790-7</ArticleId><ArticleId IdType="pubmed">3011278</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan MD, Flint M. 1997. Virus-encoded proteinases of the picornavirus super-group. J Gen Virol 78:699&#x2013;723. doi:10.1099/0022-1317-78-4-699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-78-4-699</ArticleId><ArticleId IdType="pubmed">9129643</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragovich PS, Prins TJ, Zhou R, Webber SE, Marakovits JT, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Ford CE, Burke BJ, Rejto PA, Hendrickson TF, Tuntland T, Brown EL, Meador JW III, Ferre RA, Harr JE, Kosa MB, Worland ST. 1999. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as l-glutamine replacements. J Med Chem 42:1213&#x2013;1224.</Citation><ArticleIdList><ArticleId IdType="pubmed">10197965</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Yang B, Zhai Y, Yin Z, Sun Y, Rao Z. 2015. Peptidyl aldehyde NK-1.8k suppresses enterovirus 71 and enterovirus 68 infection by targeting protease 3C. Antimicrob Agents Chemother 59:2636&#x2013;2646. doi:10.1128/AAC.00049-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00049-15</ArticleId><ArticleId IdType="pmc">PMC4394787</ArticleId><ArticleId IdType="pubmed">25691647</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai Y, Zhao X, Cui Z, Wang M, Wang Y, Li L, Sun Q, Yang X, Zeng D, Liu Y, Sun Y, Lou Z, Shang L, Yin Z. 16 November 2015. Cyanohydrin as an anchoring group for potent and selective inhibitors of enterovirus 71 3C protease. J Med Chem doi:10.1021/acs.jmedchem.5b01013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.5b01013</ArticleId><ArticleId IdType="pubmed">26571192</ArticleId></ArticleIdList></Reference><Reference><Citation>Falah N, Montserret R, Lelogeais V, Schuffenecker I, Lina B, Cortay JC, Violot S. 2012. Blocking human enterovirus 71 replication by targeting viral 2A protease. J Antimicrob Chemother 67:2865&#x2013;2869. doi:10.1093/jac/dks304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dks304</ArticleId><ArticleId IdType="pubmed">22865380</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou Z, Sun Y, Rao Z. 2014. Current progress in antiviral strategies. Trends Pharmacol Sci 35:86&#x2013;102. doi:10.1016/j.tips.2013.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2013.11.006</ArticleId><ArticleId IdType="pmc">PMC7112804</ArticleId><ArticleId IdType="pubmed">24439476</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Guo Y, Lou Z. 2012. A versatile building block: the structures and functions of negative-sense single-stranded RNA virus nucleocapsid proteins. Protein Cell 3:893&#x2013;902. doi:10.1007/s13238-012-2087-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-012-2087-5</ArticleId><ArticleId IdType="pmc">PMC4875381</ArticleId><ArticleId IdType="pubmed">23136065</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. 2011. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364:2405&#x2013;2416. doi:10.1056/NEJMoa1012912.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1012912</ArticleId><ArticleId IdType="pubmed">21696307</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. 2011. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364:1207&#x2013;1217. doi:10.1056/NEJMoa1009482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1009482</ArticleId><ArticleId IdType="pmc">PMC3153125</ArticleId><ArticleId IdType="pubmed">21449784</ArticleId></ArticleIdList></Reference><Reference><Citation>Dieterich D, Rockstroh JK, Orkin C, Gutierrez F, Klein MB, Reynes J, Shukla U, Jenkins A, Lenz O, Ouwerkerk-Mahadevan S, Peeters M, De La Rosa G, Tambuyzer L, Jessner W. 2014. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study. Clin Infect Dis 59:1579&#x2013;1587. doi:10.1093/cid/ciu675.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu675</ArticleId><ArticleId IdType="pubmed">25192745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamoral-Theys D, Decaestecker C, Mathieu V, Dubois J, Kornienko A, Kiss R, Evidente A, Pottier L. 2010. Lycorine and its derivatives for anticancer drug design. Mini Rev Med Chem 10:41&#x2013;50. doi:10.2174/138955710791112604.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138955710791112604</ArticleId><ArticleId IdType="pubmed">20105122</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedron JC, Gutierrez D, Flores N, Ravelo AG, Estevez-Braun A. 2010. Synthesis and antiplasmodial activity of lycorine derivatives. Bioorg Med Chem 18:4694&#x2013;4701. doi:10.1016/j.bmc.2010.05.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2010.05.023</ArticleId><ArticleId IdType="pubmed">20627737</ArticleId></ArticleIdList></Reference><Reference><Citation>Toriizuka Y, Kinoshita E, Kogure N, Kitajima M, Ishiyama A, Otoguro K, Yamada H, Omura S, Takayama H. 2008. New lycorine-type alkaloid from Lycoris traubii and evaluation of antitrypanosomal and antimalarial activities of lycorine derivatives. Bioorg Med Chem 16:10182&#x2013;10189. doi:10.1016/j.bmc.2008.10.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2008.10.061</ArticleId><ArticleId IdType="pubmed">19013823</ArticleId></ArticleIdList></Reference><Reference><Citation>Kretzing S, Abraham G, Seiwert B, Ungemach FR, Krugel U, Regenthal R. 2011. Dose-dependent emetic effects of the amaryllidaceous alkaloid lycorine in beagle dogs. Toxicon 57:117&#x2013;124. doi:10.1016/j.toxicon.2010.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.toxicon.2010.10.012</ArticleId><ArticleId IdType="pubmed">21055413</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang YC, Chu JJ, Yang PL, Chen W, Yates MV. 2008. Rapid identification of inhibitors that interfere with poliovirus replication using a cell-based assay. Antiviral Res 77:232&#x2013;236. doi:10.1016/j.antiviral.2007.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2007.12.009</ArticleId><ArticleId IdType="pmc">PMC7114228</ArticleId><ArticleId IdType="pubmed">18243348</ArticleId></ArticleIdList></Reference><Reference><Citation>Li SY, Chen C, Zhang HQ, Guo HY, Wang H, Wang L, Zhang X, Hua SN, Yu J, Xiao PG, Li RS, Tan X. 2005. Identification of natural compounds with antiviral activities against SARS-associated coronavirus. Antiviral Res 67:18&#x2013;23. doi:10.1016/j.antiviral.2005.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2005.02.007</ArticleId><ArticleId IdType="pmc">PMC7114104</ArticleId><ArticleId IdType="pubmed">15885816</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, Wang Q, Pan X, Fernandez de Castro I, Sun Y, Guo Y, Tao X, Risco C, Sui SF, Lou Z. 2013. Bunyamwera virus possesses a distinct nucleocapsid protein to facilitate genome encapsidation. Proc Natl Acad Sci U S A 110:9048&#x2013;9053. doi:10.1073/pnas.1222552110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1222552110</ArticleId><ArticleId IdType="pmc">PMC3670369</ArticleId><ArticleId IdType="pubmed">23569257</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabrielsen B, Monath TP, Huggins JW, Kefauver DF, Pettit GR, Groszek G, Hollingshead M, Kirsi JJ, Shannon WM, Schubert EM, DaRe J, Ugarkar B, Ussery MA, Phelan MJ. 1992. Antiviral (RNA) activity of selected Amaryllidaceae isoquinoline constituents and synthesis of related substances. J Nat Prod 55:1569&#x2013;1581. doi:10.1021/np50089a003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/np50089a003</ArticleId><ArticleId IdType="pubmed">1336040</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, Wang W, Sun Y, Ma C, Wang X, Wang X, Liu P, Shen S, Li B, Lin J, Deng F, Wang H, Lou Z. 11 November 2015. Crystal structure of the core region of hantavirus nucleocapsid protein reveals the mechanism for ribonucleoprotein complex formation. J Virol doi:10.1128/JVI.02523-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02523-15</ArticleId><ArticleId IdType="pmc">PMC4702685</ArticleId><ArticleId IdType="pubmed">26559827</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou G, Puig-Basagoiti F, Zhang B, Qing M, Chen L, Pankiewicz KW, Felczak K, Yuan Z, Shi PY. 2009. A single-amino acid substitution in West Nile virus 2K peptide between NS4A and NS4B confers resistance to lycorine, a flavivirus inhibitor. Virology 384:242&#x2013;252. doi:10.1016/j.virol.2008.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2008.11.003</ArticleId><ArticleId IdType="pmc">PMC5388927</ArticleId><ArticleId IdType="pubmed">19062063</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Li LF, Wang QY, Shang LQ, Shi PY, Yin Z. 2014. Anti-dengue-virus activity and structure-activity relationship studies of lycorine derivatives. ChemMedChem 9:1522&#x2013;1533. doi:10.1002/cmdc.201300505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cmdc.201300505</ArticleId><ArticleId IdType="pmc">PMC7162318</ArticleId><ArticleId IdType="pubmed">24574246</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D, Cai J, Yin J, Jiang J, Jing C, Zhu Y, Cheng J, Di Y, Zhang Y, Cao M, Li S, Peng Z, Hao X. 2015. Lycorine-derived phenanthridine downregulators of host Hsc70 as potential hepatitis C virus inhibitors. Future Med Chem 7:561&#x2013;570. doi:10.4155/fmc.15.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/fmc.15.14</ArticleId><ArticleId IdType="pubmed">25921398</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Yang Y, Xu Y, Ma C, Qin C, Zhang L. 2011. Lycorine reduces mortality of human enterovirus 71-infected mice by inhibiting virus replication. Virol J 8:483. doi:10.1186/1743-422X-8-483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-8-483</ArticleId><ArticleId IdType="pmc">PMC3212826</ArticleId><ArticleId IdType="pubmed">22029605</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Yuan HH, Zhang X, Li YP, Shang LQ, Yin Z. 2014. Novel lycorine derivatives as anticancer agents: synthesis and in vitro biological evaluation. Molecules 19:2469&#x2013;2480. doi:10.3390/molecules19022469.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules19022469</ArticleId><ArticleId IdType="pmc">PMC6271160</ArticleId><ArticleId IdType="pubmed">24566315</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao L, Zhu S, Wang Y, Lou Z, Sun Y. 22 August 2015. A comprehensive procedure for antiviral inhibitor discovery using EV71 as an example. Biophys Rep doi:10.1007/s41048-015-0006-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s41048-015-0006-z</ArticleId><ArticleId IdType="pmc">PMC4762143</ArticleId><ArticleId IdType="pubmed">26942222</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang L, Wang Y, Qing J, Shu B, Cao L, Lou Z, Gong P, Sun Y, Yin Z. 2014. An adenosine nucleoside analogue NITD008 inhibits EV71 proliferation. Antiviral Res 112:47&#x2013;58. doi:10.1016/j.antiviral.2014.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2014.10.009</ArticleId><ArticleId IdType="pubmed">25446894</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing J, Wang Y, Sun Y, Huang J, Yan W, Wang J, Su D, Ni C, Li J, Rao Z, Liu L, Lou Z. 2014. Cyclophilin A associates with enterovirus-71 virus capsid and plays an essential role in viral infection as an uncoating regulator. PLoS Pathog 10:e1004422. doi:10.1371/journal.ppat.1004422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004422</ArticleId><ArticleId IdType="pmc">PMC4183573</ArticleId><ArticleId IdType="pubmed">25275585</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Qing J, Sun Y, Rao Z. 2014. Suramin inhibits EV71 infection. Antiviral Res 103:1&#x2013;6. doi:10.1016/j.antiviral.2013.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2013.12.008</ArticleId><ArticleId IdType="pubmed">24374150</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmittgen TD, Livak KJ. 2008. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3:1101&#x2013;1108. doi:10.1038/nprot.2008.73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2008.73</ArticleId><ArticleId IdType="pubmed">18546601</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui HK, Qing J, Guo Y, Wang YJ, Cui LJ, He TH, Zhang L, Liu L. 2013. Stapled peptide-based membrane fusion inhibitors of hepatitis C virus. Bioorg Med Chem 21:3547&#x2013;3554. doi:10.1016/j.bmc.2013.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2013.02.011</ArticleId><ArticleId IdType="pubmed">23490158</ArticleId></ArticleIdList></Reference><Reference><Citation>Prichard MN, Shipman C Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antiviral Res 14:181&#x2013;205. doi:10.1016/0166-3542(90)90001-N.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0166-3542(90)90001-N</ArticleId><ArticleId IdType="pubmed">2088205</ArticleId></ArticleIdList></Reference><Reference><Citation>Prichard MN, Shipman C Jr. 1996. Analysis of combinations of antiviral drugs and design of effective multidrug therapies. Antivir Ther 1:9&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">11322261</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Q, Yameen M, Liu W, Gao Z, Li Y, Peng X, Cai Y, Wu C, Zheng Q, Li J, Lin T. 2013. Conformational plasticity of the 2A proteinase from enterovirus 71. J Virol 87:7348&#x2013;7356. doi:10.1128/JVI.03541-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03541-12</ArticleId><ArticleId IdType="pmc">PMC3700279</ArticleId><ArticleId IdType="pubmed">23616646</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen JF, Cherney MM, Liebig HD, Skern T, Kuechler E, James MN. 1999. The structure of the 2A proteinase from a common cold virus: a proteinase responsible for the shut-off of host-cell protein synthesis. EMBO J 18:5463&#x2013;5475. doi:10.1093/emboj/18.20.5463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/18.20.5463</ArticleId><ArticleId IdType="pmc">PMC1171615</ArticleId><ArticleId IdType="pubmed">10523291</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu Z, Wang B, Zhang X, Gao X, Qin B, Zhao Z, Cui S. 2013. Crystal structure of 2A proteinase from hand, foot and mouth disease virus. J Mol Biol 425:4530&#x2013;4543. doi:10.1016/j.jmb.2013.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2013.08.016</ArticleId><ArticleId IdType="pubmed">23973886</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano KP, Ali A, Aydin C, Soumana D, Ozen A, Deveau LM, Silver C, Cao H, Newton A, Petropoulos CJ, Huang W, Schiffer CA. 2012. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog 8:e1002832. doi:10.1371/journal.ppat.1002832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002832</ArticleId><ArticleId IdType="pmc">PMC3406087</ArticleId><ArticleId IdType="pubmed">22910833</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawitz E, Gane EJ. 2013. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 369:678&#x2013;679. doi:10.1056/NEJMc1307641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc1307641</ArticleId><ArticleId IdType="pubmed">23944316</ArticleId></ArticleIdList></Reference><Reference><Citation>Strader DB, Wright T, Thomas DL, Seeff LB. 2004. Diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147&#x2013;1171. doi:10.1002/hep.20119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.20119</ArticleId><ArticleId IdType="pubmed">15057920</ArticleId></ArticleIdList></Reference><Reference><Citation>Gradi A, Svitkin YV, Imataka H, Sonenberg N. 1998. Proteolysis of human eukaryotic translation initiation factor eIF4GII, but not eIF4GI, coincides with the shutoff of host protein synthesis after poliovirus infection. Proc Natl Acad Sci U S A 95:11089&#x2013;11094. doi:10.1073/pnas.95.19.11089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.19.11089</ArticleId><ArticleId IdType="pmc">PMC21600</ArticleId><ArticleId IdType="pubmed">9736694</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustin KE, Sarnow P. 2001. Effects of poliovirus infection on nucleo-cytoplasmic trafficking and nuclear pore complex composition. EMBO J 20:240&#x2013;249. doi:10.1093/emboj/20.1.240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/20.1.240</ArticleId><ArticleId IdType="pmc">PMC140206</ArticleId><ArticleId IdType="pubmed">11226174</ArticleId></ArticleIdList></Reference><Reference><Citation>Park N, Katikaneni P, Skern T, Gustin KE. 2008. Differential targeting of nuclear pore complex proteins in poliovirus-infected cells. J Virol 82:1647&#x2013;1655. doi:10.1128/JVI.01670-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01670-07</ArticleId><ArticleId IdType="pmc">PMC2258732</ArticleId><ArticleId IdType="pubmed">18045934</ArticleId></ArticleIdList></Reference><Reference><Citation>Almstead LL, Sarnow P. 2007. Inhibition of U snRNP assembly by a virus-encoded proteinase. Genes Dev 21:1086&#x2013;1097. doi:10.1101/gad.1535607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1535607</ArticleId><ArticleId IdType="pmc">PMC1855234</ArticleId><ArticleId IdType="pubmed">17473171</ArticleId></ArticleIdList></Reference><Reference><Citation>Badorff C, Lee GH, Lamphear BJ, Martone ME, Campbell KP, Rhoads RE, Knowlton KU. 1999. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 5:320&#x2013;326. doi:10.1038/6543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/6543</ArticleId><ArticleId IdType="pubmed">10086389</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez A, Santos A, Alonso G, Vazquez D. 1976. Inhibitors of protein synthesis in eukaryotic cells. Comparative effects of some amaryllidaceae alkaloids. Biochim Biophys Acta 425:342&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">944052</ArticleId></ArticleIdList></Reference><Reference><Citation>Vrijsen R, Everaert L, Van Hoof LM, Vlietinck AJ, Vanden Berghe DA, Boeye A. 1987. The poliovirus-induced shut-off of cellular protein synthesis persists in the presence of 3-methylquercetin, a flavonoid which blocks viral protein and RNA synthesis. Antiviral Res 7:35&#x2013;42. doi:10.1016/0166-3542(87)90037-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0166-3542(87)90037-4</ArticleId><ArticleId IdType="pubmed">3026245</ArticleId></ArticleIdList></Reference><Reference><Citation>Vrijsen R, Vanden Berghe DA, Vlietinck AJ, Boeye A. 1986. Lycorine: a eukaryotic termination inhibitor? J Biol Chem 261:505&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pubmed">3001065</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>